CME Group ($CME) will hand the CEO job from Terry Duffy to President and CFO Lynne Fitzpatrick on the later of March 1, 2027 or the filing date of its 2026 annual report, with Duffy staying on as Executive Chairman through December 31, 2027. Since the June 17, 2026 announcement, the handoff has filled in. CME has named a successor CFO, posted a record third quarter and outrun the S&P 500 by more than 18 percentage points. Here is the full record, with numbers.
The terms of the transition
CME's June 17, 2026 Form 8-K lays out the mechanics. The board approved the plan on June 16, 2026.
- Transition date: the later of March 1, 2027 and the date CME files its 2026 Form 10-K. The press release gives the date as March 1, 2027.
- Duffy: stays Chairman and CEO until the transition date, then serves as Executive Chairman through December 31, 2027. His duties in that role include facilitating "a successful CEO transition" and helping the board with governance and strategic oversight.
- Fitzpatrick: age 48, President and CFO since November 2024, CFO since April 2023, with CME since 2006 and earlier an investment banker at Credit Suisse and UBS. She joins the board and its Executive Committee on the transition date.
- Fitzpatrick's pay as CEO: a $1.2 million base salary, a target bonus of 200% of salary and a long-term incentive target of 700% of salary. Arithmetic: a $2.4 million target bonus and an $8.4 million long-term incentive target.
- Duffy's equity: his outstanding performance awards vest at target on the transition date, except the award for the period ending December 31, 2026, which vests March 15, 2027 on actual results. His 2027 long-term incentive comes as fully vested shares in September 2027.
Duffy's tenure is long by any standard. Per the press release, he became Chairman in 2002, Executive Chairman in 2006 and Chairman and CEO in 2016. CME says it averaged 28.1 million contracts a day in 2025 and carries a market value of more than $95 billion. Fitzpatrick said she was "honored to have the opportunity to succeed him as CEO next March."
What has happened since
- September 9, 2026: an 8-K named Jack Tobin, 63, Chief Accounting Officer since 2015, as Deputy CFO effective November 2, 2026. He becomes CFO in March 2027, when Fitzpatrick moves up. Matthew Render, 47, who joined from Citadel in August 2026, takes over as Chief Accounting Officer on November 2, 2026. That answers the CFO search the June 8-K promised.
- October 21, 2026: CME reported third-quarter results under Duffy, with Fitzpatrick as CFO. Revenue was $1,737.3 million, against $1,537.6 million a year earlier. Diluted EPS was $2.89, against $2.49, and adjusted diluted EPS was $3.02, against $2.68. Average daily volume reached 29.4 million contracts, a third-quarter record.
Duffy credited the volume to uncertainty: "As uncertainty intensified in Q3, clients turned to CME Group in record numbers to manage risk and capitalize on opportunities," he said in the Q3 release. CME returned nearly $1 billion to shareholders in the quarter, with $465 million in dividends and $524 million in buybacks.
The math: growth and the stock
| Metric | Q3 2025 | Q3 2026 | Change |
|---|---|---|---|
| Revenue ($M) | 1,537.6 | 1,737.3 | +12.99% |
| Diluted EPS | $2.49 | $2.89 | +16.06% |
| Adjusted diluted EPS | $2.68 | $3.02 | +12.69% |
| Average daily volume (000s) | 25,322 | 29,445 | +16.28% |
Arithmetic: $1,737.3M / $1,537.6M - 1 = 12.99%. $2.89 / $2.49 - 1 = 16.06%. $3.02 / $2.68 - 1 = 12.69%. 29,445 / 25,322 - 1 = 16.28%.
The market's first reaction was negative. $CME closed at $252.54 on June 17, 2026, down 3.46% from $261.60 on June 16. The S&P 500 fell 1.21% that day, from 7,511.35 to 7,420.10. So about two-thirds of the drop was CME-specific (3.46 minus 1.21 is 2.25 points of underperformance). The day-one read on the succession was cautious.
That discount did not last. $CME closed at $305.71 on October 23, 2026, up 21.05% from the June 17 close ($305.71 / $252.54 - 1). The S&P 500 rose 2.74% over the same span (7,623.68 / 7,420.10 - 1). For 2026 so far, $CME is up 11.95% from $273.08 at the December 31, 2025 close.
Why the succession matters to traders
CME is the venue for benchmark futures in interest rates, equity indexes, energy, metals and agriculture. An exchange's CEO sets its fee policy, its product launches and its stance in Washington. Duffy regularly testifies before Congress, and the press release credits him with the 2007 CBOT merger, the 2008 NYMEX deal and a 2025 retail venture with FanDuel.
Fitzpatrick's path runs through corporate development, treasury and finance, and investors watch whether that background shows up in capital-return and pricing decisions. The board also kept Duffy in an active role for most of 2027, so the change is gradual rather than a clean break. Competition is not standing still either: rivals are pushing into prediction markets and longer trading hours, while bond-trading platforms consolidate, as in ICE's MarketAxess deal.
What to watch
- November 2, 2026: Tobin becomes Deputy CFO and Render becomes Chief Accounting Officer.
- The 2026 Form 10-K filing: the transition cannot take effect before CME files it, so a filing after March 1, 2027 would push the handoff back.
- Fourth-quarter volume: average daily volume of 29.4 million in the third quarter is the bar for the last full quarter before the handoff.
More market-structure coverage is on the Trading Tips For You homepage.
Bull/Bear Verdict
Bull Case: The handoff is orderly. An internal successor with 20 years at CME, a named CFO successor and Duffy as Executive Chairman through 2027 limit disruption. Third-quarter revenue grew 12.99% and volume set a third-quarter record, and $CME is up 21.05% since the June 17 dip.
Bear Case: Duffy is the face of the exchange in Washington and the architect of its biggest deals. A finance-trained CEO may be more cautious just as rivals push into prediction markets, retail trading and longer hours. After a 21.05% run since June, record volume is now the expectation, and a calmer market could slow the volume that drives fees.
FAQ
When does Lynne Fitzpatrick become CEO of CME Group?
On the later of March 1, 2027 or the date CME files its 2026 annual report on Form 10-K, according to the June 17, 2026 8-K.
Is Terry Duffy leaving CME Group?
Not right away. He stays CEO until the transition date and then serves as Executive Chairman through December 31, 2027.
Who will replace Fitzpatrick as CFO?
Jack Tobin, CME's Chief Accounting Officer since 2015. He becomes Deputy CFO on November 2, 2026 and CFO in March 2027.
How has CME stock done since the announcement?
$CME fell 3.46% on June 17, 2026 to $252.54 and closed at $305.71 on October 23, 2026, a 21.05% gain from the announcement-day close.
Updated October 26, 2026: rewritten with terms from CME's June 17 Form 8-K and press release, the September CFO succession filing, third-quarter 2026 results and price data through the October 23, 2026 close. Clarification: the original gave the effective date simply as March 1, 2027. The filing sets it as the later of that date and the 2026 10-K filing date.